Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Conditions: Advanced Carcinoid Tumor; Advanced Neuroendocrine Neoplasm; Atypical Carcinoid Tumor; Locally Advanced Neuroendocrine Neoplasm; Malignant Bronchial Neoplasm; Metastatic Carcinoid Tumor; Metastatic Neuroendocrine Neoplasm; Unresectable Carcinoid Tumor; Unr esectable Neuroendocrine Neoplasm Interventions: Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials